USANA

TheraTarget, Inc. is a biopharmaceutical company based in Salt Lake City, Utah, specializing in the development of polymer-drug conjugate delivery systems for clinical use. With a patented drug delivery platform, TheraTarget's innovative technology has shown promising results in preclinical testing, demonstrating high response rates, immunoactivation, and long-term suppression of tumor recurrence in solid tumors. Driven by a mission to optimize immunotherapy, TheraTarget's management team and board of directors bring decades of expertise in polymer therapeutics, nanomedical applications, product development, manufacturing, quality control monitoring, and successful completion of clinical trials. In addition to cancer treatment, TheraTarget's pipeline includes preclinically proven agents for neuromodulation, showcasing the company's commitment to advancing medical solutions in various clinical arenas.Generated from the website

Curza is a small-molecule therapeutics company based in Salt Lake City, UT, dedicated to developing novel classes of antibiotics to combat the global threat of antibiotic resistance. With a focus on infectious diseases, Curza has developed several structurally distinct classes of proprietary drugs, including CZ-02, a new class of broad spectrum antibiotics targeting drug-resistant Gram-negative bacteria. Driven by the rising epidemic of antibiotic resistance, Curza's goal is to address the urgent need for effective antibiotics, as antibiotic resistance contributes to the death of 5,000,000 people annually. Through their innovative ribosomal antibiotics program, Curza aims to develop antibiotics that show both selectivity and potent activity against ESKAPE pathogens, while also focusing on developing antibiofilm antibiotics to combat biofilm-related infections.Generated from the website

About Q Therapeutics Q Therapeutics is an emerging biopharmaceutical company that utilizes cell-based technologies to develop new treatments for debilitating diseases of the central nervous system ( CNS ). Our company was founded based on the pioneering work of Dr. Mahendra Rao at the University of Utah. In 2004, we began the process of translating decades of research at the University of Utah and the National Institute of Health ( NIH ) into practical new therapeutic products. Our exclusive licenses with these institutions have resulted in 16 issued patents, with many more pending. Q's initial development efforts have focused on natural cell-based products that replace insulating myelin on damaged neurons and produce growth factors and other support for neurons, with the goal of restoring normal neuron function. Our first product, called Q-Cells , is designed to address a wide range of diseases, including multiple sclerosis ( MS ), transverse myelitis, ALS ( Lou Gehrig's Disease ), cerebral palsy, spinal cord injury, traumatic brain injury, stroke, Parkinson's Disease and Alzheimer's Disease. Our patented cellular technologies and manufacturing processes, combined with an experienced management team and a focused strategy, will enable us to develop a comprehensive product pipeline to treat CNS diseases in ways no existing drug can. Q has patents covering cells that give rise to the entire central nervous system. Both Q-Cells and other of Q's cell types can be made available under collaborative research or licensing arrangements.